IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
Rhea-AI Summary
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, announced that CEO and co-founder William Ho will present at NobleCon20 on December 3, 2024, at 10:30 am ET. The presentation will be available through a high-definition video webcast on the company's investor relations website, Noble Capital Markets' Conference website, and Channelchek platform. The webcast recording will remain accessible for 90 days after the event on all three platforms.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, INAB gained 20.77%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET.
A high-definition video webcast of the presentation will be available the following day on the Company's website https://investors.in8bio.com/news-events/events-presentations, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek www.channelchek.com the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investors and Corporate Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com
Patrick McCall, CFO
IN8bio, Inc
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
When is IN8bio (INAB) presenting at NobleCon20?
Where can I watch IN8bio's NobleCon20 presentation?
How long will IN8bio's NobleCon20 presentation be available online?
What type of therapies does IN8bio (INAB) develop?
